Compare AbbVie Inc (ABBV) vs Bit Digital Inc (BTBT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Bit Digital Inc — how do they compare? AbbVie Inc trades at $253.68 (market cap $449.91B), while Bit Digital Inc trades at $1.67 (market cap $583.11M). The key difference: AbbVie Inc is far larger — about 771.6× Bit Digital Inc's market cap, and AbbVie Inc pays a 2.72% dividend while Bit Digital Inc pays none. Which is the better fit depends on your goals.
| ABBV | BTBT | |
|---|---|---|
Market Cap | $449.91B | $583.11M |
Sector | Health | Technology |
52-Week High | $261.07 | $4.22 |
52-Week Low | $184.85 | $1.27 |
Enterprise Value | $513.38B | $872.41M |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
BTBT trades at $1.74, up 5.45% in the past 24 hours, but faces bearish technical signals with 14 sell indicators. The company reported a net loss of $80.32 million in 2025 with a negative net income margin of -145.45%, though revenue reached $113.56 million. Recent news highlights a $100 million loan facility for WhiteFiber and a $20 million Ethereum purchase, signaling strategic moves in AI infrastructure and digital assets.
The outlook remains challenging due to persistent losses and high cash burn, but analyst consensus is 100% buy with potential from strategic investments. Key risks include execution on new ventures, competitive pressures, and reliance on financing amid negative operating cash flow.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Bit Digital Inc
Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.
Read more on BTBT →
